| Project/Area Number |
15K20528
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
MURAKAMI Jun 岡山大学, 大学病院, 助教 (40362983)
SOGAWA Chiharu 岡山大学, 大学院医歯薬学総合研究科, 講師 (10253022)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | セツキシマブ / 口腔癌 / PI3K阻害剤 / PIK３CA / Ca9-22 / PIK3CA / アービタックス |
|---|
| Outline of Final Research Achievements |
Cetuximab is expected as an anti-EGFR antibody molecule targeting drug for oral cancer.However, cases in which EGFR gene mutation has occurred due to continued administration and tolerance has been acquired, and cases in which the response is not responded due to the presence of the downstream KRAS gene mutation are problems.
Gene variation analysis was performed on nine cancer cell lines showing association with cetuximab.In Ca9-22 strain and HSG strain mutation was observed against PIK3CA.This result suggested that PIK3CA may be less susceptible to cetuximab.From the results of this study, it was proved in this study that mutation of PIK3CA gene greatly affects response rate in administration of cetuximab.
|
